Li J - Search Results

1

Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors.

Gao J, Li J, Li Y, Li Z, Gong J, Wu J, Liu N, Dong B, Qi C, Li J, Shen L. Gao J, et al. Among authors: li y, li j, li z. Oncotarget. 2016 May 24;7(21):30241-9. doi: 10.18632/oncotarget.7148. Oncotarget. 2016. PMID: 26848617 Free PMC article.

2

Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients.

Li J, Gong JF, Li J, Gao J, Sun NP, Shen L. Li J, et al. World J Gastroenterol. 2012 Feb 21;18(7):698-703. doi: 10.3748/wjg.v18.i7.698. World J Gastroenterol. 2012. PMID: 22363143 Free PMC article. Clinical Trial.

3

[Challenges of gastrointestinal stromal tumor in the era of targeted therapy].

Shen L, Li J. Shen L, et al. Among authors: li j. Zhonghua Wei Chang Wai Ke Za Zhi. 2012 Mar;15(3):204-7. Zhonghua Wei Chang Wai Ke Za Zhi. 2012. PMID: 22454158 Chinese.

4

Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors.

Li J, Gao J, Hong J, Shen L. Li J, et al. Future Oncol. 2012 May;8(5):617-24. doi: 10.2217/fon.12.29. Future Oncol. 2012. PMID: 22646775

5

C-KIT mutations were closely associated with the response to Imatinib in Chinese advanced gastrointestinal stromal tumor patients.

Gao J, Dang Y, Sun N, Li J, Shen L. Gao J, et al. Among authors: li j. Med Oncol. 2012 Dec;29(5):3039-45. doi: 10.1007/s12032-012-0308-7. Epub 2012 Jul 20. Med Oncol. 2012. PMID: 22815156

6

[Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].

Hong JL, Li J, Li J, Shen L. Hong JL, et al. Among authors: li j. Zhonghua Bing Li Xue Za Zhi. 2012 Jun;41(6):386-90. doi: 10.3760/cma.j.issn.0529-5807.2012.06.006. Zhonghua Bing Li Xue Za Zhi. 2012. PMID: 22932406 Chinese.

7

Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors.

Gao J, Tian Y, Li J, Sun N, Yuan J, Shen L. Gao J, et al. Among authors: li j. Med Oncol. 2013 Jun;30(2):522. doi: 10.1007/s12032-013-0522-y. Epub 2013 Mar 2. Med Oncol. 2013. PMID: 23456621

8

[Efficacy observation on imatinib adjuvant therapy with longer duration in patients with gastrointestinal stromal at intermediate or high risk of recurrence].

Li J, Dang YZ, Gao J, Shen L. Li J, et al. Zhonghua Wei Chang Wai Ke Za Zhi. 2013 Mar;16(3):216-20. Zhonghua Wei Chang Wai Ke Za Zhi. 2013. PMID: 23536338 Chinese.

9

PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs).

Li J, Dang Y, Gao J, Li Y, Zou J, Shen L. Li J, et al. Among authors: li y. Med Oncol. 2015 Apr;32(4):111. doi: 10.1007/s12032-015-0554-6. Epub 2015 Mar 11. Med Oncol. 2015. PMID: 25757539

10

[Mutation profiles of c-kit/PDGFRα and its associations with clinicopathological characteristics in Chinese gastrointestinal stromal tumors: analysis of 827 cases].

Li Y, Gao J, Tian Y, Li J, Shen L. Li Y, et al. Among authors: li j. Zhonghua Wei Chang Wai Ke Za Zhi. 2015 Apr;18(4):332-7. Zhonghua Wei Chang Wai Ke Za Zhi. 2015. PMID: 25940173 Chinese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

191,128 results

Search Page

Filters